International Journal of Microbiology / 2010 / Article / Tab 1

Research Article

Clinical and Microbiological Determinants of Outcome in Staphylococcus aureus Bacteraemia

Table 1

Clinical Characteristics of 100 cases of S. aureus bacteraemia identified prospectively from 2006 to 2007.

Clinical CharacteristicsTotalUncomplicatedComplicatedRR95% CI

Age
 Median65.56761.386*
  (with IQR)(46–78)(42–77)(49–78)

Male Gender59 (%)40 (54.8%)19 (70.4%)1.280.94–1.50.096

Patient Location
 Admission Unit27(%)14 (19.2%)13 (48.1%)1.561.07–2.28.006
 ICU11(%)10 (13.7%)1 (3.7%)0.780.62–0.98.280
 Renal Unit19(%)16 (21.9%)3 (11.1%)0.840.66–1.06.265
 Medical Wards30(%)25 (34.2%)5 (18.5%)0.820.65–1.03.148
 Surgical Wards13(%)8 (10.9%)5 (18.5%)1.210.78–1.90.329

 Community Acquired7(%)4 (5.5%)3 (11.1%)1.300.68–2.49.384

 Community Onset33(%)19 (26.0%)14 (51.9%)1.401.021.92.018

Comorbidities
 Diabetes Mellitus20(%)10 (13.7%)10 (37.3%)1.581.002.48.021
 IDU7(%)1 (1.4%)6 (22.2%)5.420.8833.49.001
 Smoker22(%)13 (17.8%)9 (33.3%)1.300.90–1.88.109
 Excess Alcohol11(%)9 (12.3%)2 (7.4%)0.880.65–1.20.722
 HIV000
 Haemodialysis17(%)14 (19.2%)3 (11.1%)0.860.67–1.12.55
 Central line in situ43(%)38 (52%)5 (18.5%)0.690.55–0.88.003
 Recent Antibiotics26(%)21 (28.8%)5 (18.5%)0.870.69–1.11.442
 Recent Steroid Therapy12(%)9 (12.3%)3 (11.1%)0.970.68–1.381.000
 Recent Immunosuppression6(%)4 (5.5%)2 (7.4%)1.100.62–1.96.660

Management
Primary Focus Removed
72 hours41(%)36 (49.3%)5 (18.5%)0.710.57–0.90.006
72 hours/not removed36(%)22 (30.1%)14 (51.8%)1.300.98–1.74.061
 Not identified23(%)15 (20.5%)8 (29.6%)1.160.83–1.60.423
Initiation of effective antibiotics ≥ 48 hours32 (%)18 (24.7%)14 (51.9%)2.101.22–3.61.015
Duration of IV treatment 2 weeks66(%)47 (64.4%)19 (70.4%)1.070.84–1.37.641

Outcome
Mortality (all cause at 30 days)38/97**24/73 (32.9%)14/25** (56%)1.290.99–1.70.057
(39.2%)

P-value adjusted for ties. **two patients with complicated bacteraemia were lost to follow up at 30 days.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.